Why Zoetis (ZTS) Cut 2026 Guidance After Weaker Pet Demand And What It Means Now

• In early May 2026, Zoetis Inc. reported first-quarter sales of US$2,262 million, essentially flat net income year on year, and lowered its full-year 2026 revenue and earnings guidance after weaker-than-expected performance in its U.S. companion animal business.
• Management pointed to increased price sensitivity among pet owners, fewer veterinary visits, and rising competition, especially in key companion animal categories, as the main factors weighing on results and prompting the revised outlook.
• We’ll now examine how this guidance cut, driven by softness in U.S. companion animal demand, reshapes Zoetis’ previously optimistic investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Zoetis Investment Narrative Recap

To own Zoetis today, you need to believe that its global animal health leadership, diversified across companion animals and livestock, can absorb a weaker U.S. pet market and still create value over time. The guidance cut highlights that the near term catalyst has flipped: investors are now watching whether U.S. companion animal trends stabilize, while intensifying competition in dermatology and parasiticides has become the most immediate risk to the story.

The updated full year 2026 guidance to US$9.680–9.960 billion in revenue and US$2.680–2.760 billion in reported net income is the announcement that matters most here, because it formally bakes the softer U.S. companion animal demand and higher price sensitivity into management’s base case and will likely frame how investors judge any recovery in visits, pricing, and prescription volumes over the next few quarters.

Yet behind the stock’s sharp drop, investors should be aware that competition in Zoetis’ core pet franchises could...

Read the full narrative on Zoetis (it's free!)

Zoetis' narrative projects $10.9 billion revenue and $3.2 billion earnings by 2028.

Uncover how Zoetis' forecasts yield a $151.00 fair value, a 73% upside to its current price.

Exploring Other Perspectives

Some analysts were far more optimistic before this setback, assuming Zoetis could reach about US$11.6 billion in revenue and US$3.2 billion in earnings by 2029, so if you share that view you are effectively betting that U.S. companion animal headwinds and rising competitive pressure prove temporary rather than a lasting drag on the story.

Explore 9 other fair value estimates on Zoetis - why the stock might be worth just $127.00!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Zoetis research is our analysis highlighting 6 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Zoetis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zoetis' overall financial health at a glance.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Capitalize on the AI infrastructure supercycle with our selection of the 40 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 33 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com